ProCE Banner Activity

ATLAS-INH: Phase III Trial of Fitusiran Prophylaxis in Patients With Hemophilia A or B With Inhibitors

Slideset Download
Conference Coverage
Monthly fitusiran prophylaxis significantly reduced the rate of bleeding events and improved quality of life for individuals with hemophilia A or B with inhibitors compared with on-demand bypassing agents.

Released: December 21, 2021

Expiration: December 20, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation